Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 128
interventional 110
Observational 17
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 72
Drug|Other 11
Drug|Other|Procedure|Radiation 5
Drug|placebo 5
Drug|Procedure 4
Other|Procedure 3
Procedure 2
Biological 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Procedure|Radiation 1
Biological|Genetic|Other|Procedure 1
Biological|Other 1
Drug|Genetic|Other|Procedure 1
Drug|Radiation 1
Other 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 54
Japan 3
United States|Canada 3
Denmark 2
Italy 2
Peru 2
United Kingdom 2
United States|Australia|Canada 2
United States|Canada|Czechia|France|Germany|Hungary|Poland|Spain|United Kingdom 2
United States|Italy 2
Algeria|Argentina|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Germany|Greece|Hungary|Ireland|Israel|Italy|Mexico|Morocco|Poland|Portugal|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Thailand|Tunisia 1
Australia|Austria|Belgium|China|Czechia|France|Germany|Hungary|Ireland|Italy|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
Australia|Belgium|Bulgaria|Chile|China|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Portugal|Russian Federation|South Africa|Spain|Sweden|Thailand|Turkey 1
Australia|Belgium|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Spain|United Kingdom 1
Australia|Belgium|Canada|France|Germany|Hungary|India|Israel|Italy|Korea, Republic of|Spain|Turkey 1
Austria 1
Austria|Belgium|Bulgaria|Canada|Chile|France|Germany|Mexico|Norway|Portugal|Sweden|Thailand 1
Austria|Belgium|Bulgaria|Canada|Germany|Greece|Italy|Japan|Russian Federation|Spain|Turkey 1
Austria|Belgium|Bulgaria|Czech Republic|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine 1
Austria|Bulgaria|Czech Republic|France|Hungary|Poland|Slovakia|Ukraine 1
Austria|Bulgaria|Czechia|France|Germany|Hungary|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine 1
Canada 1
China|Japan|Korea, Republic of|Taiwan 1
France 1
France|Germany|Ireland|Italy|United Kingdom 1
France|Germany|Italy|Poland|United Kingdom 1
Germany 1
NA 1
Spain 1
Switzerland 1
United States|Argentina|Australia|Belgium|Canada|China|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Netherlands|Russian Federation|Spain|Thailand|Turkey|United Kingdom 1
United States|Australia 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Netherlands|Poland|Romania|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|France|Germany 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Germany|Italy|United Kingdom 1
United States|Belarus|Canada|Czechia|France|Georgia|Germany|Hungary|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Belgium|Germany|Ireland|Italy|Spain|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Netherlands|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Spain|United Kingdom 1
United States|France 1
United States|France|Italy|United Kingdom 1
United States|Germany|Switzerland 1
United States|Italy|Netherlands|Spain|Sweden 1

Sites per Study

Site_count Study_Count
1 37
2 8
3 5
4 1
5 6
6 5
7 2
8 3
9 3
10 3
11 2
12 1
13 1
18 1
20 1
21 2
22 2
23 2
25 2
26 1
27 1
29 1
35 3
38 1
47 1
48 1
52 1
58 1
59 1
65 2
67 1
70 1
76 1
96 1
102 1
104 1
114 1
124 1
273 1

Phase

Phase Study_Count
Phase 2 49
Phase 3 18
Phase 1 17
Phase 1/Phase 2 13
N/A 9
Phase 4 3
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 63
2 27
3 5
4 8
5 3
6 1
7 1
NA 2

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 72 5.00000 10.00000 24.00000 8.00000 30.0000 48.0
1st Qu. 72 44.00000 24.00000 47.00000 35.00000 150.7500 51.5
Median 72 80.00000 36.00000 50.00000 51.00000 175.0000 55.0
Mean 72 81.44444 43.29412 68.61538 81.42857 319.7222 153.0
3rd Qu. 72 102.00000 61.00000 77.00000 94.00000 248.2500 205.5
Max. 72 195.00000 100.00000 166.00000 400.00000 2233.0000 356.0

Trial Group Type

group_type Group_Count
Experimental 152
Active Comparator 29
Other 8
Placebo Comparator 2
NA 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 65
Parallel Assignment 41
Sequential Assignment 3
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 104
Other 3
Supportive Care 2
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 5
France 4
United States|Italy 2
Czechia|Germany|Israel|Italy|Spain|United Kingdom 1
Switzerland|United Kingdom 1
United Kingdom 1
United States|Canada|Italy|United Kingdom 1
United States|Puerto Rico 1
United States|Russian Federation 1

Sites per Study

Site_count Study_Count
1 7
2 3
6 1
7 2
11 1
22 1
30 1
266 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 80.0000
Median 153.0000
Mean 524.5294
3rd Qu 726.0000
Max 2544.0000

Observation Model

observational_model Study_Count
Cohort 7
NA 4
Other 3
Case-Control 2
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 9
Other 4
Retrospective 2
Cross-Sectional 1
NA 1

Registries

Studies by Country

Country Study_Count
Canada 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 5000
1st Qu 5000
Median 5000
Mean 5000
3rd Qu 5000
Max 5000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Other 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04173494 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) https://ClinicalTrials.gov/show/NCT04173494 Recruiting Sierra Oncology, Inc. 2021-12-31
NCT03373877 Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis https://ClinicalTrials.gov/show/NCT03373877 Active, not recruiting Samus Therapeutics, Inc. 2020-10-31
NCT03333486 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer https://ClinicalTrials.gov/show/NCT03333486 Recruiting Roswell Park Cancer Institute 2022-09-06
NCT03289910 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT03289910 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT01787487 Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm https://ClinicalTrials.gov/show/NCT01787487 Recruiting M.D. Anderson Cancer Center 2020-07-26
NCT03065400 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03065400 Completed Icahn School of Medicine at Mount Sinai 2020-05-28
NCT03003325 The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV https://ClinicalTrials.gov/show/NCT03003325 Active, not recruiting Fondazione per la Ricerca Ospedale Maggiore 2022-06-30
NCT02966353 Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. https://ClinicalTrials.gov/show/NCT02966353 Completed Novartis 2018-07-24
NCT02038036 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. https://ClinicalTrials.gov/show/NCT02038036 Completed Novartis 2015-09-29
NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT03165734 Recruiting CTI BioPharma 2022-07-31
NCT01433445 Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis https://ClinicalTrials.gov/show/NCT01433445 Completed Novartis 2020-06-22
NCT02556931 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies https://ClinicalTrials.gov/show/NCT02556931 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2021-07-31
NCT02523638 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients https://ClinicalTrials.gov/show/NCT02523638 Completed AOP Orphan Pharmaceuticals AG 2015-12-31
NCT02515630 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) https://ClinicalTrials.gov/show/NCT02515630 Completed Sierra Oncology, Inc. 2017-07-18
NCT02493530 TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea https://ClinicalTrials.gov/show/NCT02493530 Active, not recruiting Vanderbilt-Ingram Cancer Center 2020-12-31
NCT02436135 Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease https://ClinicalTrials.gov/show/NCT02436135 Completed Gilead Sciences 2017-11-20
NCT02407080 Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02407080 Completed Icahn School of Medicine at Mount Sinai 2018-12-19
NCT02386800 CINC424A2X01B Rollover Protocol https://ClinicalTrials.gov/show/NCT02386800 Recruiting Novartis 2025-09-17
NCT02311569 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation https://ClinicalTrials.gov/show/NCT02311569 Completed Swiss Group for Clinical Cancer Research 2016-12-31
NCT02292446 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. https://ClinicalTrials.gov/show/NCT02292446 Completed Novartis 2017-12-29
NCT02218047 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. https://ClinicalTrials.gov/show/NCT02218047 Active, not recruiting AOP Orphan Pharmaceuticals AG 2021-04-30
NCT02129101 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies https://ClinicalTrials.gov/show/NCT02129101 Completed Mayo Clinic 2016-12-31
NCT02124746 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02124746 Completed Sierra Oncology, Inc. 2018-12-06
NCT02101268 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF https://ClinicalTrials.gov/show/NCT02101268 Completed Sierra Oncology, Inc. 2016-07-28
NCT02098161 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis https://ClinicalTrials.gov/show/NCT02098161 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT02087059 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis https://ClinicalTrials.gov/show/NCT02087059 Completed Novartis 2015-03-31
NCT01369498 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01369498 Completed Gilead Sciences 2014-06-05
NCT01981850 A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01981850 Active, not recruiting Promedior, Inc. 2017-08-30
NCT01969838 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01969838 Completed Sierra Oncology, Inc. 2016-09-12
NCT01949805 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera https://ClinicalTrials.gov/show/NCT01949805 Completed AOP Orphan Pharmaceuticals AG 2016-07-31
NCT01901432 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera https://ClinicalTrials.gov/show/NCT01901432 Completed Italfarmaco 2017-06-26
NCT01816256 Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT01816256 Completed University Health Network, Toronto 2019-03-11
NCT01787552 A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF https://ClinicalTrials.gov/show/NCT01787552 Completed Novartis 2018-04-10
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01692366 Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly https://ClinicalTrials.gov/show/NCT01692366 Completed Sanofi 2014-03-31
NCT01632904 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study https://ClinicalTrials.gov/show/NCT01632904 Completed Incyte Corporation 2014-03-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01558739 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) https://ClinicalTrials.gov/show/NCT01558739 Completed Novartis 2014-01-31
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01520220 Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT01520220 Completed Eli Lilly and Company 2015-06-26
NCT01499147 Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01499147 Completed University of Illinois at Chicago 2013-05-31
NCT01493414 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. https://ClinicalTrials.gov/show/NCT01493414 Completed Novartis 2017-01-26
NCT01445769 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT01445769 Completed Incyte Corporation 2013-03-31
NCT01423851 Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF https://ClinicalTrials.gov/show/NCT01423851 Active, not recruiting NS Pharma, Inc. 2020-11-30
NCT01420783 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT01420783 Completed Sanofi 2012-11-30
NCT01392443 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF https://ClinicalTrials.gov/show/NCT01392443 Completed Novartis 2017-10-31
NCT01387763 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms https://ClinicalTrials.gov/show/NCT01387763 Active, not recruiting Odense University Hospital 2020-01-31
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01348490 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) https://ClinicalTrials.gov/show/NCT01348490 Completed Incyte Corporation 2018-12-19
NCT04432168 The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence https://ClinicalTrials.gov/show/NCT04432168 Recruiting Leiden University Medical Center 2022-04-30
NCT04282187 Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT04282187 Recruiting University of Washington 2024-11-11
NCT04262141 IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) https://ClinicalTrials.gov/show/NCT04262141 Recruiting University of Miami 2023-08-31
NCT04182100 Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply https://ClinicalTrials.gov/show/NCT04182100 Recruiting PharmaEssentia Japan K.K. 2021-04-30
NCT04116502 MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera https://ClinicalTrials.gov/show/NCT04116502 Recruiting University of Birmingham 2026-08-01
NCT04057040 Hepcidin Mimetic in Patients With Polycythemia Vera https://ClinicalTrials.gov/show/NCT04057040 Recruiting Protagonist Therapeutics, Inc. 2022-08-01
NCT03952039 An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT03952039 Recruiting Celgene 2021-11-24
NCT03907436 The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase https://ClinicalTrials.gov/show/NCT03907436 Completed University of California, Irvine 2019-10-01
NCT03895112 MPN-RC 118 AVID200 in Myelofibrosis https://ClinicalTrials.gov/show/NCT03895112 Recruiting Icahn School of Medicine at Mount Sinai 2021-03-31
NCT03878199 Ruxolitinib and Daunorubicin (CPX-351) in Treating Patients With Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT03878199 Recruiting OHSU Knight Cancer Institute 2021-12-31
NCT03862157 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03862157 Recruiting M.D. Anderson Cancer Center 2024-01-01
NCT03755518 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib https://ClinicalTrials.gov/show/NCT03755518 Recruiting Celgene 2022-05-19
NCT03669965 KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera https://ClinicalTrials.gov/show/NCT03669965 Recruiting Kartos Therapeutics, Inc. 2022-06-30
NCT03662126 KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor https://ClinicalTrials.gov/show/NCT03662126 Recruiting Kartos Therapeutics, Inc. 2021-08-01
NCT03627403 Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors https://ClinicalTrials.gov/show/NCT03627403 Recruiting University of Utah 2024-03-14
NCT03624335 Influence of Umbilical Cord Clamping Time in the Newborn https://ClinicalTrials.gov/show/NCT03624335 Completed Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana 2016-03-31
NCT03441113 Extended Access of Momelotinib in Adults With Myelofibrosis https://ClinicalTrials.gov/show/NCT03441113 Enrolling by invitation Sierra Oncology, Inc. 2024-12-31
NCT01259856 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01259856 Completed Icahn School of Medicine at Mount Sinai 2017-06-30
NCT01259817 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01259817 Completed Icahn School of Medicine at Mount Sinai 2016-12-31
NCT01243944 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) https://ClinicalTrials.gov/show/NCT01243944 Completed Incyte Corporation 2014-01-15
NCT01243073 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera https://ClinicalTrials.gov/show/NCT01243073 Completed Geron Corporation 2013-10-31
NCT01236638 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT01236638 Completed Sierra Oncology, Inc. 2014-06-30
NCT01200498 Study of SB939 in Subjects With Myelofibrosis https://ClinicalTrials.gov/show/NCT01200498 Completed M.D. Anderson Cancer Center 2012-11-30
NCT01193699 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera https://ClinicalTrials.gov/show/NCT01193699 Completed AOP Orphan Pharmaceuticals AG 2018-01-25
NCT01187108 Study of Cobalt’s Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru https://ClinicalTrials.gov/show/NCT01187108 Completed University of Colorado, Denver 2013-09-30
NCT01134120 A Study in Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT01134120 Completed Eli Lilly and Company 2014-04-30
NCT01120821 Treatment of Polycythemia Vera With Gleevec https://ClinicalTrials.gov/show/NCT01120821 Completed Weill Medical College of Cornell University 2007-01-31
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00946270 Pomalidomide for Myelofibrosis Patients https://ClinicalTrials.gov/show/NCT00946270 Completed M.D. Anderson Cancer Center 2018-05-22
NCT00931762 Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis https://ClinicalTrials.gov/show/NCT00931762 Completed Novartis 2011-08-31
NCT00928707 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera https://ClinicalTrials.gov/show/NCT00928707 Completed Italfarmaco 2011-07-31
NCT00910728 Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases https://ClinicalTrials.gov/show/NCT00910728 Completed AstraZeneca 2012-03-31
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT03972943 CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT03972943 Recruiting University of Utah 2024-05-01
NCT01423058 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT01423058 Completed Sierra Oncology, Inc. 2014-06-30
NCT04051307 Dual Vaccine Trial in Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT04051307 Recruiting Herlev Hospital 2022-07-10
NCT02577926 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia https://ClinicalTrials.gov/show/NCT02577926 Recruiting RWTH Aachen University 2020-12-31
NCT00935987 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) https://ClinicalTrials.gov/show/NCT00935987 Completed Sierra Oncology, Inc. 2012-04-30
NCT00807677 A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00807677 Completed Millennium Pharmaceuticals, Inc. 2012-09-30
NCT03935555 Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib https://ClinicalTrials.gov/show/NCT03935555 Recruiting Samus Therapeutics, Inc. 2020-05-15
NCT03136185 IMG-7289 in Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT03136185 Recruiting Imago BioSciences,Inc. 2020-12-31
NCT00745550 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis https://ClinicalTrials.gov/show/NCT00745550 Completed S*BIO 2012-01-31
NCT00588991 Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00588991 Active, not recruiting National Cancer Institute (NCI) 2014-02-01
NCT00586651 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis https://ClinicalTrials.gov/show/NCT00586651 Completed Teva Pharmaceutical Industries 2009-10-31
NCT00509899 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis https://ClinicalTrials.gov/show/NCT00509899 Completed Incyte Corporation 2007-12-31
NCT00445744 Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome https://ClinicalTrials.gov/show/NCT00445744 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00430066 Effects of Imatinib Mesylate in Polycythemia Vera https://ClinicalTrials.gov/show/NCT00430066 Completed Niguarda Hospital 2009-11-30
NCT00424970 Treatment of High Altitude Polycythemia by Acetazolamide https://ClinicalTrials.gov/show/NCT00424970 Completed Association pour la Recherche en Physiologie de l’Environnement NA
NCT00397813 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00397813 Completed Fred Hutchinson Cancer Research Center 2017-09-30
NCT00381550 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00381550 Completed National Cancer Institute (NCI) 2011-03-31
NCT00357305 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00357305 Completed National Cancer Institute (NCI) 2011-11-30
NCT00255346 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) https://ClinicalTrials.gov/show/NCT00255346 Completed M.D. Anderson Cancer Center 2017-03-03
NCT00241241 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera https://ClinicalTrials.gov/show/NCT00241241 Completed PV-Nord 2006-10-31
NCT00227591 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00227591 Completed National Cancer Institute (NCI) 2010-12-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00052520 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00052520 Completed Fred Hutchinson Cancer Research Center 2011-04-30
NCT00047190 Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia https://ClinicalTrials.gov/show/NCT00047190 Completed National Cancer Institute (NCI) 2007-04-30
NCT00039416 Imatinib Mesylate in Treating Patients With Myelofibrosis https://ClinicalTrials.gov/show/NCT00039416 Completed National Cancer Institute (NCI) 2007-08-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00038675 Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate https://ClinicalTrials.gov/show/NCT00038675 Completed M.D. Anderson Cancer Center 2013-11-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03263364 Genomic Screening for Hereditary Erythrocytosis and Related Diseases https://ClinicalTrials.gov/show/NCT03263364 Recruiting Centre Hospitalier Universitaire Dijon 2020-10-31
NCT02912884 Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure https://ClinicalTrials.gov/show/NCT02912884 Active, not recruiting University Hospital, Geneva 2020-07-31
NCT02897297 Myeloproliferative Neoplastic Diseases Observatory From Brest https://ClinicalTrials.gov/show/NCT02897297 Recruiting University Hospital, Brest 2025-09-30
NCT02893410 Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients https://ClinicalTrials.gov/show/NCT02893410 Completed University Hospital, Brest 2015-12-31
NCT02823184 Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms https://ClinicalTrials.gov/show/NCT02823184 Completed University Hospital, Bordeaux 2019-04-27
NCT02252159 Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) https://ClinicalTrials.gov/show/NCT02252159 Active, not recruiting Incyte Corporation 2019-08-31
NCT01970930 Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients https://ClinicalTrials.gov/show/NCT01970930 Completed Icahn School of Medicine at Mount Sinai 2016-06-02
NCT01420224 Study of the Effects of Commercial Air Travel on the Lungs https://ClinicalTrials.gov/show/NCT01420224 Completed University of Oxford 2011-06-30
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT03745378 Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) https://ClinicalTrials.gov/show/NCT03745378 Completed Fondazione per la Ricerca Ospedale Maggiore 2018-07-07
NCT00722527 Molecular Biology of Polycythemia and Thrombocytosis https://ClinicalTrials.gov/show/NCT00722527 Recruiting University of Utah 2020-07-31
NCT00715247 Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes https://ClinicalTrials.gov/show/NCT00715247 Completed University of Utah 2018-12-31
NCT00666549 Research Tissue Bank https://ClinicalTrials.gov/show/NCT00666549 Completed Icahn School of Medicine at Mount Sinai 2017-03-27
NCT00666289 Familial Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00666289 Completed Icahn School of Medicine at Mount Sinai 2015-01-20
NCT00665067 Correlative Biomarker Study in Patients With Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00665067 Completed Icahn School of Medicine at Mount Sinai 2018-07-20
NCT00495638 Pulmonary Hypertension, Hypoxia and Sickle Cell Disease https://ClinicalTrials.gov/show/NCT00495638 Completed National Institutes of Health Clinical Center (CC) NA
NCT00433862 Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders https://ClinicalTrials.gov/show/NCT00433862 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry https://ClinicalTrials.gov/show/NCT02760238 Recruiting University Health Network, Toronto 2025-10-31